The expression of migration stimulating factor, a potent oncofetal cytokine, is uniquely controlled by 3′-untranslated region-dependent nuclear sequestration of its precursor messenger RNA

Cancer Research

Volumn 65, Issue 23, 2005, Pages 10742-10749

  Kay, Richard A ^a   Ellis, Ian R ^a   Jones, Sarah J ^a   Perrier, Stéphane ^a   Florence, Margaret M ^a   Schor, Ana M ^a   Schor, Seth L ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FIBRONECTIN; ISOPROTEIN; MESSENGER RNA; MESSENGER RNA PRECURSOR; MIGRATION STIMULATING FACTOR; RNA; TRANSFORMING GROWTH FACTOR BETA1;

3' UNTRANSLATED REGION; ADULT; ARTICLE; CARCINOGENESIS; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; FETUS; FETUS CELL; FIBROBLAST; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INTRON; MOLECULAR CLONING; MOLECULAR SIZE; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SECRETION; REPORTER GENE; RNA PROCESSING; TUMOR CELL;

3' UNTRANSLATED REGIONS; ADULT; AMINO ACID SEQUENCE; CELL LINE; CELL NUCLEUS; CYTOKINES; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR SEQUENCE DATA; RNA PRECURSORS; SUBCELLULAR FRACTIONS;

EID: 28244433111     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2038     Document Type: Article

References (34)

1. Schor SL, Ellis IR, Jones SJ, et al. Migration-stimulating factor: a genetically truncated onco-fetal fibronectin isoform expressed by carcinoma and tumor-associated stromal cells. Cancer Res 2003;63:8827-36.
2. Schor SL, Schor AM, Grey AM, Rushton G. Foetal and cancer patient fibroblasts produce an automne migration stimulating factor not made by normal adult cells. J Cell Sci 1988;90:391-9.
3. Schor SL, Schor AM, Characterization of migration stimulating activity (MSF): evidence for its role in cancer pathogenesis. Cancer Invest 1990;8:665-7.
4. Schor SL, Schor AM, Grey AM, Chen J, Rushton G, Ellis I. Mechanism of action of the migration stimulating factor produced by fetal and cancer patient fibroblasts: effect on hyaluronic acid synthesis. Tn Vitro 1989;25: 737-46.
5. Ellis I, Grey AM, Schor AM, Schor SL. Antagonistic effects of transforming growth factor 3 and MSF on fibroblast migration and hyaluronic acid synthesis: possible implications for wound healing. J Cell Sci 1992;102:447-56.
6. Schor SL, Schor AM, Keatch RP, Belch J. Role of matrix macromolecules in the etiology and treatment of chronic ulcers. In: Lee BY, editor. The wound management manual. New York: McGraw-Hill; 2005. p. 109-21.
7. Picardo M, Schor SL, Grey AM, et al. Migration stimulating activity in serum of breast cancer patients. Lancet 1991;37:130-3.
8. Schor SL, Schor AM. Stromal acceleration of tumour progression: role of "fetal-like" fibroblast subpopulations. Pathol Update 1997;4:75-95.
9. Schor SL, Schor AM. Tumour-stroma interactions. Phenotypic and genetic alterations in mammary stroma: implications for tumour progression. Breast Cancer Res 2001;3:373-9.
10. Edmonds M. A history of poly A sequences: from formation to factors to function. Prog Nucleic Acid Res Mol Biol 2002;71:285-389.
11. Hynes R. Fibronectins. New York: Springer-Verlag; 1990.
12. Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Tamaki K. Epidermal growth factor induces fibronectin expression in human dermal fibroblasts via protein kinase Cδ signaling pathway, J Invest Dermatoi 2004;122: 1390-8.
13. Holbrook KA, Hennings H. Phenotypic expression of epidermal cells in vitro: a review. J Invest Dermatol 1983;81:ll-24s,
14. Becher B, Antel JP. Comparison of phenotypic and functional properties of immediately ex vivo and cultured human adult microglia. Glia 1996;18:1-10.
15. Chen Ch-YA, Shyu A-B. AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci 1995;20:465-70.
16. Gueydan C, Droogmans L, Chalon P, Huez G, Caput D, Kruys V. Identification of TIAR as a protein binding to the transcriptional regulatory AU-rich element of tumor necrosis factor α mRNA. J Biol Chem 1999;274: 2322-6.
17. Gallouzi I-E, Brennan CM, Stenberg MG. et al. HuR binding to cytoplasmic mRNA is perturbed by heat shock. Proc Natl Acad Sci U S A 2000;97:3073-8.
18. Rouault T, Klausner R. Regulation of iron metabolism in eukaryotes, CUIT Top Cell Regul 1997;35:1-19.
19. McGowan KM, Police S, Winslow JB, Pekala PH. Tumour necrosis factor-α regulation of glucose transporter (GLUT1) mRNA turnover. Contribution of the 3′-untranslated region of the GLUT1 message. J Biol Chem 1997;272:1331-7.
20. Di Liegro CM, Bellafiore M, Izquierdo JM, Rantanen A, Cuezva JM. 3′ -Untranslated regions of oxidative phosphorylation mRNAs function in vivo as enhancers of translation. Biochem J 2000;252:109-15.
21. Ostareck-Lederer DH, Ostareck DH, Standart N, Thiele BJ. Translation of 15-lipoxygenase mRNA is inhibited by a protein that binds to a repeated sequence in the 3′ untranslated region. EMBO J 1994;13:1476-81.
22. Mazumder B, Seshadri V, Fox PL. Translational control by the 3′-UTR: the ends specify the means. Trends Biochem Sci 2003;28:91-8.
23. Keene JD. Ribonucleoprotein infrastructure regulating the flow of genetic information between the genome and the proteome. Proc Natl Acad Sci U S A 2001;98: 7018-24.
24. Keene JD. Organizing mRNA export. Nat Genet 2003; 23:111-2.
25. Curtis D, Lehmann R, Zamore PD. Translational regulation in development. Cell 1995;81:171-8.
26. Bilenoglu O, Basak AN, Russell JE, A 3′ UTR mutation affects β-globin expression without altering the stability of its fully processed mRNA. Br J Haematol 2002;119: 1106-14.
27. Timchenko LT. Myotonic dystrophy: the role of RNA CUG triplet repeats. Am J Hum Genet 1999;64:360-4.
28. Keski-Oja J, Raghow R, Sawdey M, et al. Regulation of mRNAs for type-1 plasminogen activator inhibitor, fibronectin and type I procollagen by transforming growth factor-β: divergent responses in lung fibroblasts and carcinoma cells. J Biol Chem 1988;263: 3111-5.
29. Borsi L, Castellani P, Risso AM, Leprini A, Zardi L. Transforming growth factor-β regulates the splicing pattern of fibronectin messenger RNA precursor. FEBS Lett 1990;261:175-8.
30. Wrana JL, Overall CM, Sodek J. Regulation of the expression of a secreted acidic protein rich in cyteine (SPARC) in human fibroblasts by transforming growth factor β. Comparison of transcriptional and post-transcriptional control with fibronectin and type 1 collagen. Eur J Biochem 1991;197:519-28,
31. Akhurst RJ, Derynck R. TGF-β signaling in cancer-a double-edged sword. Trends Cell Biol 2001;11:844-51.
32. Cui W, Fowlis DJ, Bryson S, et al. TGF-β1 inhibits the formation of benign skin tumours but enhances progression to invasive spindle cell carcinomas in transgenic mice. Cell 1996;86:531-42.
33. Glick AB. TGFβ1, back to the future: revisiting its role as a transforming growth factor. Cancer Biol Ther 2004; 3:276-83.
34. Dunning AM, Ellis PD, McBride S, et al. A transforming growth factorβ1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 2003;63:2610-5.